eShowcase: CogState DataPoint
Web-based system puts sponsors running brain function clinical trials in the know
Web-based system puts sponsors running brain function clinical trials in the know
CogState Ltd. (Melbourne, Australia) has released the first real-time cognitive data monitoring system, called DataPoint, which allows pharmaceutical companies to access, monitor, and review data from global, multicenter trials at a central and secure Web-based location. The tool is targeted toward trials where cognitive function is the primary endpoint and represents a significant technological departure from paper and pencil cognitive brain function measurements.
One of the main benefits, says CogState, is that DataPoint enables clinical researchers to respond much more quickly to data coming out of clinical trials. For example, DataPoint delivers cleaned datasets and cognitive reports to pharmaceutical clients within hours of study completion, compared to the usual weeks. DataPoint also functions as the main point of contact between sponsors and CogState, and all study-specific software and manuals required to upload data and run a trial are accessible from one central source.
CogState Ltd., +61-3-9664-1300, www.cogstate.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
